Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer.
McGale J, Khurana S, Huang A, Roa T, Yeh R, Shirini D, Doshi P, Nakhla A, Bebawy M, Khalil D, Lotfalla A, Higgins H, Gulati A, Girard A, Bidard FC, Champion L, Duong P, Dercle L, Seban RD. McGale J, et al. Among authors: champion l. J Clin Med. 2023 Jul 25;12(15):4882. doi: 10.3390/jcm12154882. J Clin Med. 2023. PMID: 37568284 Free PMC article. Review.
Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy.
Grambow-Velilla J, Seban RD, Chouahnia K, Assié JB, Champion L, Girard N, Bonardel G, Matton L, Soussan M, Chouaïd C, Duchemann B. Grambow-Velilla J, et al. Among authors: champion l. Cancers (Basel). 2023 Apr 10;15(8):2223. doi: 10.3390/cancers15082223. Cancers (Basel). 2023. PMID: 37190152 Free PMC article.
[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.
Seban RD, Arnaud E, Loirat D, Cabel L, Cottu P, Djerroudi L, Hescot S, Loap P, Bonneau C, Bidard FC, Huchet V, Jehanno N, Berenbaum A, Champion L, Buvat I. Seban RD, et al. Among authors: champion l. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):4024-4035. doi: 10.1007/s00259-023-06394-y. Epub 2023 Aug 22. Eur J Nucl Med Mol Imaging. 2023. PMID: 37606858
Predictors of toxicity after curative reirradiation with intensity modulated radiotherapy or proton therapy for recurrent head and neck carcinoma: new dose constraints for pharyngeal constrictors muscles and oral cavity.
Beddok A, Maynadier X, Krhili S, Ala Eddine C, Champion L, Chilles A, Goudjil F, Zefkili S, Amessis M, Choussy O, Le Tourneau C, Buvat I, Créhange G, Carton M, Calugaru V. Beddok A, et al. Among authors: champion l. Strahlenther Onkol. 2023 Oct;199(10):901-909. doi: 10.1007/s00066-023-02080-y. Epub 2023 May 31. Strahlenther Onkol. 2023. PMID: 37256301
Curative high-dose reirradiation for patients with recurrent head and neck adenoid cystic carcinomas: outcomes and analysis of patterns of failure.
Mahé M, Beddok A, Goudjil F, Ala Eddine C, Bolle S, Champion L, Feuvret L, Herman P, Zefkili S, Choussy O, Le Tourneau C, Dendale R, Buvat I, Sauvaget E, Créhange G, Calugaru V. Mahé M, et al. Among authors: champion l. Int J Radiat Biol. 2024;100(1):79-86. doi: 10.1080/09553002.2023.2242934. Epub 2023 Aug 21. Int J Radiat Biol. 2024. PMID: 37526368
Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial.
Rodrigues M, Vanoni G, Loap P, Dubot C, Timperi E, Minsat M, Bazire L, Durdux C, Fourchotte V, Laas E, Pouget N, Castel-Ajgal Z, Marret G, Lesage L, Meseure D, Vincent-Salomon A, Lecompte L, Servant N, Vacher S, Bieche I, Malhaire C, Huchet V, Champion L, Kamal M, Amigorena S, Lantz O, Chevrier M, Romano E. Rodrigues M, et al. Among authors: champion l. Nat Commun. 2023 Jun 22;14(1):3698. doi: 10.1038/s41467-023-39383-8. Nat Commun. 2023. PMID: 37349318 Free PMC article. Clinical Trial.
120 results